Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+).

Trial Profile

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 25 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Jul 2011 Planned End Date changed from 1 Nov 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top